Guggenheim dropped their price objective on Valeant Pharmaceuticals Intl from $300.00 to $195.00 and set a buy rating for the company in a research note on Friday, November 6th.
Advertisement
Jerusalem knife attacker shot dead: Israeli police
The incidents came after three terror attacks on Thursday, in an ongoing wave of Palestinian attacks since September. The Palestinians were “attempting to damage the security fence by throwing rocks and hurling burning tyres at it.
Approximately six weeks ago, Valeant’s board formed an ad hoc committee to investigate the recent allegations made against Philidor, including claims that Valeant management was involved in the alleged wrongdoing at Philidor. They have since recovered, helped in part as its largest investor, Bill Ackman’s Pershing Square Capital Management, increased its stake.
Canandaigua man legally changes name to Darth Vader
He is now on the Bone Marrow Transplant list at Seattle’s VA Puget Sound Health Care System in Washington state. Vader recently watched Star Wars: The Force Awakens, and said he liked the movie.
Valeant Pharmaceuticals is facing more pressure from a high ranking USA politician who says the company has obstructed a congressional investigation into drug pricing activities by failing to disclose information as requested. “So that’s what we’re going to do”, Pearson said Wednesday. Because Valeant owns a highly diversified, divisible, and desirable portfolio of products that can be soldproduct-by- product and/or division-by-division in an industry with many well-capitalizedbuyers, it could deleverage at an even more rapid rate if it chose to do so. After the Philidor scandal, Valeant has been in the spotlight to take all the political risk but this move slightly shields it from that risk because of lower prices. We ended our relationship and now we have Walgreens.
Purported message from jihadist leader
He is thought to constantly move between Islamic State strongholds in Raqqa, Syria, and Mosul, Iraq, to avoid airstrikes. Baghdadi said the USA and its allies have “learned from” recent lengthy wars in Iraq and Afghanistan.
The Walgreens agreement will also be used as a model for distribution deals with independent retail pharmacies.
When looking at the daily charts for Valeant Pharmaceuticals, the stock has been in a strong downtrend. He noted the government does not approve of these programs or allow them in healthcare plans like Medicare. The accord comes amid an outcry over skyrocketing drug prices. It predicted no major deals next year but said it hoped to do some small purchases.
Valeant has been accused of using Philidor to create a network of “phantom pharmacies” to steer pharmacy benefit managers toward Valeant’s more expensive drugs, rather than cheaper alternatives.
Valeant has been under intense scrutiny because of its drug pricing practices, but the firm has agreed to sell brand name ophthalmology and dermatology medications at a 10% discount through drug-store giant Walgreens. It has also pledged to cut prices. Analysts were expecting earnings to be $14.27 per share on sales of $12.55 billion.
Valeant had previously expected to have earnings per share of between $11.67 and $11.87 per share with revenue of between $11 billion and $11.2 billion.
About 22 percent in the ISI Evercore poll expected cash earnings of $6.5 billion and 18 percent expected $6.75 billion.
For 2015, the Canadian drugmaker expects an adjusted profit of $10.23 to $10.33 per share on sales of $10.4 billion to $10.5 billion.
Advertisement
Morgan Stanley reissued their hold rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a report published on Tuesday, ARN reports.
